YMAB Y-mAbs Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: YMAB

Price (delayed)

$17.15

Market cap

$750.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.49

Enterprise value

$673.56M

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product ...

Highlights
The company's debt fell by 20% YoY and by 13% QoQ
The quick ratio has grown by 20% YoY and by 3.9% from the previous quarter
The EPS has soared by 78% YoY but it has contracted by 9% from the previous quarter
The net income has soared by 78% YoY but it has contracted by 11% from the previous quarter
Y-mAbs Therapeutics's equity has decreased by 8% YoY
The gross margin has contracted by 2.1% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ymabs.com
Peers: OMER OMGA

Key stats

What are the main financial stats of YMAB
Market
Shares outstanding
43.78M
Market cap
$750.78M
Enterprise value
$673.56M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.41
Price to sales (P/S)
8.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.94
Earnings
Revenue
$84.82M
EBIT
-$25.67M
EBITDA
-$24.94M
Free cash flow
-$27.23M
Per share
EPS
-$0.49
Free cash flow per share
-$0.62
Book value per share
$2.32
Revenue per share
$1.94
TBVPS
$2.87
Balance sheet
Total assets
$127.87M
Total liabilities
$26.88M
Debt
$1.42M
Equity
$100.99M
Working capital
$90.98M
Liquidity
Debt to equity
0.01
Current ratio
5.52
Quick ratio
5.02
Net debt/EBITDA
3.1
Margins
EBITDA margin
-29.4%
Gross margin
86.5%
Net margin
-25.3%
Operating margin
-30.3%
Efficiency
Return on assets
-16.3%
Return on equity
-20.7%
Return on invested capital
-123%
Return on capital employed
-23.8%
Return on sales
-30.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

YMAB stock price

How has the Y-mAbs Therapeutics stock price performed over time
Intraday
-0.58%
1 week
16.59%
1 month
18.93%
1 year
179.32%
YTD
151.47%
QTD
5.47%

Financial performance

How have Y-mAbs Therapeutics's revenue and profit performed over time
Revenue
$84.82M
Gross profit
$73.4M
Operating income
-$25.67M
Net income
-$21.43M
Gross margin
86.5%
Net margin
-25.3%
The company's net margin has surged by 83% YoY but it fell by 22% QoQ
The operating margin has soared by 79% YoY but it has contracted by 19% from the previous quarter
The net income has soared by 78% YoY but it has contracted by 11% from the previous quarter
YMAB's operating income has surged by 73% year-on-year but it is down by 9% since the previous quarter

Growth

What is Y-mAbs Therapeutics's growth rate over time

Valuation

What is Y-mAbs Therapeutics stock price valuation
P/E
N/A
P/B
7.41
P/S
8.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.94
The EPS has soared by 78% YoY but it has contracted by 9% from the previous quarter
YMAB's P/B is 196% above its last 4 quarters average of 2.5 and 16% above its 5-year quarterly average of 6.4
Y-mAbs Therapeutics's equity has decreased by 8% YoY
The stock's price to sales (P/S) is 185% more than its last 4 quarters average of 3.1
YMAB's revenue is up by 30% year-on-year but it is down by 9% since the previous quarter

Efficiency

How efficient is Y-mAbs Therapeutics business performance
The company's return on invested capital has surged by 96% YoY and by 20% QoQ
The ROS has soared by 79% YoY but it has contracted by 19% from the previous quarter
Y-mAbs Therapeutics's ROA has soared by 73% YoY but it has decreased by 14% from the previous quarter
Y-mAbs Therapeutics's return on equity has surged by 73% YoY but it has decreased by 13% QoQ

Dividends

What is YMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for YMAB.

Financial health

How did Y-mAbs Therapeutics financials performed over time
The current ratio has grown by 20% YoY and by 4.7% from the previous quarter
The quick ratio has grown by 20% YoY and by 3.9% from the previous quarter
The company's debt is 99% lower than its equity
YMAB's debt to equity has plunged by 50% from the previous quarter and by 50% YoY
The company's debt fell by 20% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.